2012 CIS Advanced PID School May 17, 2012
and
2012 CIS Annual Meeting: Primary Immune Deficiency Disease North American Conference May 17 - 20, 2012

Friday, May 18, 2012
Zurich Ballroom (Swissotel Chicago)
Ralph Scott Shapiro, MD, Midwest Immunology Clinic, Plymouth, MN
Subcutaneous Immunoglobulin (SCIg) Therapy by Rapid Push is Preferred to Infusion by Pump: Update of a Previously Published Retrospective Analysis A retrospective chart review involved 173 PIDD patients over 1140 visits (mean age, 25.6 yrs; range, 0-68) who chose to self-administer SCIg (16% or 20%) via infusion pump or rapid push technique. If switching from IVIg, dose conversion to SCIg was on a 1:1 basis. Serum Ig levels increased from a mean trough of 848.2 mg/dL (SD, 363.4) on IVIg to a steady state mean of 1104.4 mg/dL (SD, 290.3) on SCIg. Mean infusion sites per dose were lower with rapid push (1.3) vs pump (1.8). Mean number of doses per week were 2.3 with pump and 2.8 with rapid push. Mean serum Ig levels were higher among push vs pump users (1149 vs 1064 mg/dL). A majority of patients using rapid push infused in <9 minutes. Adverse events (AEs) were reported with rapid push on 116/705 visits (16.5%), compared with 66/335 visits (19.7%) in patients using a pump. The majority (>85%) of AEs were local injection site reactions. More patients starting out with rapid push stayed with their chosen method (75.8%) compared with pump users (53.1%).